

Basilea Pharmaceutica

18th August 2026

Delivering on significant promise

Share Price (CHF)	54.2
CP Fair Value (CHF)	120

Market Cap (CHFm)	726.6
Cash (CHFm)	105.3
EV (CHFm)	621.3

Country	Switzerland
Code	BSLN
Index	SIX


The H1'26 period at Basilea was characterised by another good financial performance from the anti-fungal Cresemba (isavuconazole), with end market sales (to March '26) of \$782m (+27%). Strong underlying demand was reflected in an increase in royalty income to CHF 57.8m (+10.9%). The result was boosted by the receipt of BARDA payments, largely with respect to fosmanogepix, as well as ceftibuten-ledaborbactam. Based on the H1 performance, and with expectations for continued strong delivery, the company has increased revenue guidance for FY'26 from +10% previously to +15% and operating profit from +20% to +40%, Basilea ended H1'26 with cash and equivalents of CHF 176m and an improved net cash position of CHF 105.3m. The upgraded operating performance of the business is also reflected in the company's stated confidence in delivering its Agenda 2030 cash flow guidance of cumulative cash flows of CHF 600m.

Looking forward to 2030

Basilea recently set out its ambitions for the mid-term future of the company with Agenda 2030. Initially, we look forward to Zevtera (ceftobiprole) helping to bridge the gap following the expected entry of Cresemba generics in Q4 '27 in the US, and H2 '28 in Europe. Following its commercial launch in July '25, we believe that Zevtera's attraction particularly in the bacteraemia indication is reflected in an observed increase in the number of hospitals ordering and should be boosted by partner IST Therapeutics as it broadens its hospital coverage. Importantly for us, the long-term future of the antifungal franchise looks secure given the accumulating data from Expanded Access with fosmanogepix and the observation that global Phase 3 trials in invasive candidiasis and invasive moulds are on track. The importance of fosmanogepix has been reflected in the FDA conferring Fast Track status for various invasive fungal infections with a broad spectrum of activity against most of the fungal infections highlighted by the WHO fungal priority pathogens list. We expect sales of fosmanogepix to ultimately comfortably exceed those of Cresemba, and we forecast peak sales of circa \$1.2bn.

Healthy pipeline prospects

Given recent pipeline progress, we believe that the future of the anti-infective pipeline at Basilea looks secure. In particular, the addition of the novel oral beta-lactam/beta-lactamase inhibitor ceftibuten-ledaborbactam suggests significant commercial potential in the treatment of multidrug-resistant cUTI caused by Gram-negative *Enterobacterales*. With positive data and a peak sales potential of \$450m, we look forward to this programme entering Phase 3 in mid-2027. The highlight of the earlier stage pipeline was BAL 2420 entering the clinic and the receipt of further CARB-X funding.



Source: Calvine Partners Research

Dr Brian White
Partner
bw@calvinepartners.com

Andrew Keith
Partner
ak@calvinepartners.com

Disclosures

Calvine Partners LLP is authorised and regulated by the Financial Conduct Authority for UK investment advisory and arranging activities.

This publication has been commissioned and paid for by Basilea Pharmaceutica and as defined by the FCA is not independent research. This report is considered a marketing communication under FCA Rules. It has not been prepared under the laws and requirements established to promote the independence of investment research. It is not subject to any prohibition on dealing ahead of the dissemination of investment research. This information is widely available to the public.

This report in the United Kingdom is directed at investment professionals, certified high net worth individuals, high net worth entities, self-certified sophisticated investors, and eligible counterparties as defined by the Financial Services and Markets Act 2000 (Financial Promotion) Order 2000. The report may also be distributed and made available to persons to whom Calvine Partners is lawfully permitted. This publication is not intended for use by any individual or entity in any jurisdiction or country where that use would breach law or regulations or which would subject Calvine Partners or its affiliates to any registration requirement within such jurisdiction or country.

Calvine Partners may provide, or seek to provide, services to other companies mentioned in this report. Partners, employees, or related parties may hold positions in the companies mentioned in the report subject to Calvine Partners' personal account dealing rules.

Calvine Partners has only used publicly available information believed to be reliable at the time of this publication and made best efforts to ensure that the facts and opinions stated are fair, accurate, timely and complete at the publication date. However, Calvine Partners provides no guarantee concerning the accuracy or completeness of the report or the information or opinions within. This publication is not intended to be an investment recommendation, personal or otherwise, and it is not intended to be advice and should not be treated in any way as such. Any valuation estimates, such as those derived from a discounted cash flow, price multiple, or peer group comparison, do not represent estimates or forecasts of a future company share price. In no circumstances should the report be relied on or acted upon by non-qualified individuals. Personal or otherwise, it is not intended to be advice and should not be relied on in any way as such.

Forward-looking statements, information, estimates and assumptions contained in this report are not yet known, and uncertainties may cause the actual results, performance or achievements to be significantly different from expectations.

This report does not constitute an offer, invitation or inducement to engage in a purchase or sale of any securities in the companies mentioned. The information provided is for educational purposes only and this publication should not be relied upon when making any investment decision or entering any commercial contract. Past performance of any security mentioned is not a reliable indicator of future results and readers should seek appropriate, independent advice before acting on any of the information contained herein. This report should not be considered as investment advice, and Calvine Partners will not be liable for any losses, costs or damages arising from the use of this report. The information provided in this report should not be considered in any circumstances as personalised advice.

Calvine Partners LLP, its affiliates, officers or employees, do not accept any liability or responsibility with regard to the information in this publication. None of the information or opinions in this publication has been independently verified. Information and opinions are subject to change after the publication of this report, possibly rendering them inaccurate and/or incomplete.

Any unauthorised copying, alteration, distribution, transmission, performance, or display, of this report, is prohibited.